IOMEPROL

First approved in 2022

Details

Stereochemistry	MIXED
Molecular Formula	C17H22I3N3O8
Molecular Weight	777.0853
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

InChI

InChIKey=NJKDOADNQSYQEV-UHFFFAOYSA-N

InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)

HIDE SMILES / InChI

Molecular Formula	C17H22I3N3O8
Molecular Weight	777.0853
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://imaging.bracco.com/us-en/bracco-s-iomeron-iomeprol-contrast-agent-optimizes-multidetector-ct-images
Curator's Comment: Description is created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/10852647

Iomeprol is a nonionic, monomeric iodinated contrast medium. Iomeprol helps optimize images obtained with sophisticated multidetector computed tomography (MDCT) technology, especially for neurological, brain, liver, cardiac and vascular scanning. The mechanism of action of Iomeprol is as a X-Ray Contrast Activity. Launched by the Bracco Group in 1995, Iomeprol (Iomeron) currently is registered in more than 40 countries worldwide, including all major European markets, Japan, and major Middle East and Asian Pacific countries.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Arteriovenous malformations 2 Sources: http://www.eisai.jp/medical/products/di/EPI/IOM_V_EPI.pdf	Diagnostic	Approved 8429	Iomeprol Approved Use For cerebral angiography Launch Date 1992
Abnormalities of the urinary system, including the kidneys, ureters, and bladder 1 Sources: http://www.eisai.com/news/enews200833pdf.pdf	Diagnostic	Approved 8429	Iomeprol Approved Use For intravenous urography Launch Date 1992
Coronary artery disease 48 Sources: http://www.eisai.jp/medical/products/di/EPI/IOM_V_EPI.pdf	Diagnostic	Approved 8429	Iomeprol Approved Use For Angiocardiography Launch Date 1992

PubMed

Title	Date	PubMed
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.	2003 Apr	12690428
[Feasibility and optimization of the combined injection of contrast medium and normal saline with a single-syringe CT injection system].	2003 Jun	12811699
Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent.	2003 Jun	12773687
Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency.	2003 May 15	12745095
Pain in femoral arteriography. A double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers.	2003 Nov	14616202
Fate of pharmaceuticals--photodegradation by simulated solar UV-light.	2003 Sep	12871743
Acute sialadenitis after percutaneous coronary intervention.	2004 Jul	15243768
MR-based assessment of potential living related liver donors.	2004 Jun	15503375
Multislice CT anatomy of hepatic artery in patients undergoing liver transplantation using 3D reconstructions.	2004 Oct	15525890
Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis.	2004 Oct	15361864
[Intrathyroidal iodine concentration after application of non-ionic contrast media with and without prophylactic application of perchlorate].	2005	16163410
Irradiation in presence of iodinated contrast agent results in radiosensitization of endothelial cells: consequences for computed tomography therapy.	2005 Aug 1	16029811
Analysis of iodinated X-ray contrast agents in water samples by ion chromatography and inductively-coupled plasma mass spectrometry.	2005 Aug 26	16106857
Photocatalytic degradation of carbamazepine, clofibric acid and iomeprol with P25 and Hombikat UV100 in the presence of natural organic matter (NOM) and other organic water constituents.	2005 Jan-Feb	15644249
MDCT angiography of the pulmonary arteries: influence of iodine flow concentration on vessel attenuation and visualization.	2005 Jun	15908557
Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro.	2005 Jun	15845795
Congenital anomalies of the coronary arteries: imaging with contrast-enhanced, multidetector computed tomography.	2005 Jun	15756551
Image assessment with multislice CT coronary angiography.	2005 Mar	15775888
A 16-slice multidetector computed tomography protocol for evaluation of the gastroepiploic artery grafts in patients after coronary artery bypass surgery.	2005 Sep	15906037
Multidetector CT in abdominal aortic aneurysm treated with endovascular repair: are unenhanced and delayed phase enhanced images effective for endoleak detection?	2006 Dec	17032909
Effects of iodinated contrast media on common carotid and brachial artery blood flow and wall shear stress.	2006 Dec	16733684
16-MDCT aortography with a low-dose contrast material protocol.	2006 Feb	16423941
Characterization of acute and chronic myocardial infarcts by multidetector computed tomography: comparison with contrast-enhanced magnetic resonance.	2006 Feb 14	16461822
Multidetector CT with double arterial phase and high-iodine-concentration contrast agent in the detection of hepatocellular carcinoma.	2006 Mar	16671376
Improving diagnostic accuracy of MDCT coronary angiography in patients with mild heart rhythm irregularities using ECG editing.	2006 Mar	16498089
High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: iopromide 370 versus iomeprol 400.	2006 Mar	16481919
Contrast bolus optimization for cardiac 16-slice computed tomography: comparison of contrast medium formulations containing 300 and 400 milligrams of iodine per milliliter.	2006 May	16625109
Usefulness of saline pushing in reduction of contrast material dose in abdominal CT: evaluation of time-density curve for the aorta, portal vein and liver.	2007 Apr	17038409

Patents

Sample Use Guides

In Vivo Use Guide

IOMERON 300 Injection: each mL of IOMERON contains 612.4 mg (equivalent to 300 mg of iodine) of iomeprol. Radiological examination IOMERON 300 - 5 - 15 mL Thoracic angiography IOMERON 300 5 - 50 mL Abdominal angiography IOMERON 300 - 5 - 60 mL Peripheral anogiography IOMERON 300 - 10 - 80 mL Intravenous digital subtraction angiography IOMERON 300 - 10 - 50 mL Intraarterial digital subtraction angiography IOMERON 300 - 3 - 40 mL The dosage may be adjusted depending on the patient’s age, body weight, symptoms and purpose of use. In the case of multiple-dose administration, a total dosage of 250 mL should not be exceeded.

Route of Administration: Intravenous

In Vitro Use Guide

Iomeprol induced a time- and dose-dependent inhibition of MTT conversion in LLC-PK1-cells (75%-19% of control) at concentrations ranging from 4.7 to 75 mg I/mL after an incubation time of 2 hours and 64%-14% of control after 24 hours.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:50:10 GMT 2023` Edited by `admin` on `Fri Dec 15 17:50:10 GMT 2023`
Record UNII	17E17JBP8L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOMEPROL

Official Name

English

E-7337

Code

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE

Systematic Name

English

IOMEPROL [MI]

Common Name

English

IOMEPROL [JAN]

Common Name

English

IOMERON 300

Brand Name

English

iomeprol [INN]

Common Name

English

E7337

Code

English

Iomeprol [WHO-DD]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-

Systematic Name

English

IOMEPROL [USAN]

Common Name

English

IOMEPROL [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

V08AB10